EASL 2019 – Viking to push the limits of its Nash contender
Encouraging results from Viking Therapeutics’ lead Nash project have prompted the company to ask how low it can go.
EASL 2019 preview – Viking and Spring Bank abstracts pique early interest
High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
Intercept's Nash hopes rest on Ocaliva's borderline hit
Intercept’s Regenerate trial in Nash, one of the hottest clinical readouts of 2019, is technically a success, but toxicity casts a long shadow.
Gilead’s first big Nash bash ends in the trash
The failure of the Stellar-4 study of selonsertib is a big blow for Gilead, but has not dented enthusiasm for other Nash players.
Albireo comes up to IBAT in Nash
Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.
AASLD 2018 – Viking lands blow in early Nash skirmish
Viking’s VK2809 looks at least as good as Madrigal’s MGL-3196 in liver disease – but investors should be careful of making comparisons.
Upcoming events – Eidos and Conatus look to catch up with big pharma rivals
Trailing the leaders in amyloidosis and Nash, the respective small caps Eidos and Conatus look to mid-stage trial readouts to demonstrate their relevance.
Viking sails on favourable Nash winds
Positive phase II data delight investors, but Madrigal Pharmaceuticals leads in the race to market.
Viking squares up to Madrigal
It’s time for Viking, a Nash player that has climbed in tandem with one of its biotech peers, to prove itself.
